The pharmacokinetics of pyrazinamide (PZA) in patients with human immunodeficiency virus (HIV)-related tuberculosis are incompletely characterized. Serum PZA concentrations were determined at 2, 6, and 10 h after dosing in 48 subjects with HIV-related tuberculosis. Estimates of drug exposure using 2-h concentrations and 2-and 3-time point estimates of area under time-concentration curves (AUCs) were compared. For daily dosing, 2-h concentrations less than low and very low literature-defined cut points (i.e., 20 and 10 mg/L) were noted for 2 subjects (4%) and 1 subject (2%), respectively. For intermittent PZA dosing, 1 subject (4%) had a 2-h concentration that was less than the low cut point (25 mg/L). Correlations between 2-h concentration and AUC estimates based on 2-or 3-time point concentration determinations were strong. In HIV-infected persons receiving antituberculosis regimens containing PZA, lower-than-expected 2-h concentrations are uncommon. For therapeutic monitoring of PZA drug exposure, determination of a 2-h postdose concentration appears as reliable as 2-or 3-time point estimates of the AUC for PZA.
Tuberculosis (TB) is the most important serious opportunistic infection in HIV-infected persons worldwide, because of the spread of HIV infection into regions in which TB has long been prevalent [1] [2] [3] . The outcomes of treatment of HIV-related TB with standard rifampin-based regimens have generally been good [2] [3] [4] . However, cases and instances of delayed response, failure, and relapse have been reported in which lowerthan-expected serum concentrations of anti-TB drugs occurred [5] [6] [7] [8] [9] [10] [11] .
HIV-infected persons have been reported to have impaired absorption or altered pharmacokinetics (PK) of a variety of medications, including antimycobacterial agents [12] . HIV-infected persons receiving treatment for disseminated Mycobacterium avium infection may have significantly impaired absorption of antimycobacterial agents, including rifampin, ciprofloxacin, and ethambutol, which are also used to treat TB [12] . Reports of alterations in absorption or PK of antimycobacterial agents preceded the advent of protease inhibitor and nonnucleoside antiretroviral agents that, through competing effects on hepatic microsomal enzyme systems, increase the potential for PK interactions, altered serum concentrations, and altered drug exposure [13] . Furthermore, monorifamycin resistance has emerged during or after multidrug anti-TB treatment of HIV-related TB [4, [14] [15] [16] [17] [18] . Although anecdotal instances of lower-than-expected concentrations of anti-TB medications have been reported, how often they occur is not certain. Whether altered absorption or PK of anti-TB agents contributes significantly to the development of acquired drug resistance in patients with HIV-related TB is also uncertain.
Pyrazinamide is an essential component of modern anti-TB chemotherapy. Its use in the induction phase of TB treatment allows the duration of treatment to be shortened from 9 to 6 months. It is also an important component of TB treatment in individuals who are intolerant of or whose infections are resistant to isoniazid or rifampin, and it is important for treatment of latent TB after exposure to multidrug-resistant TB isolates [4, 19] . Estimating the absorption of and exposure to anti-TB drugs in clinical settings can be difficult, because the dosing intervals typically encompass several drug half-lives. As a result, trough levels are low and give little information about the extent of absorption or drug exposure. The usual approach has been to use drug concentrations measured 2 h after dosing as estimates of peak levels [9, 12, 20] . Two-h levels, however, are affected by rate and extent of absorption and may not provide adequate information on variability in drug exposure caused by differences in drug metabolism and/or elimination rates. Determination of drug concentrations at numerous time points throughout the dosing interval can provide a characterization of the area under time-concentration curve (AUC). Although the AUC is generally an excellent measure of drug exposure, the many samples that must be obtained and analyzed create problems of practicality and cost for routine clinical use. Whether sampling strategies that use 2 or 3 time points improve on the information obtained from a single 2-h serum concentration is uncertain.
We sought to characterize the PK of pyrazinamide in HIVinfected persons being treated for TB, to estimate the frequency and extent of substantial reductions in pyrazinamide exposure, and to determine whether a sparse but logistically feasible sampling strategy of measuring drug concentrations at 2 or 3 time points could substantially improve on measuring the 2-h concentration alone as an estimate of anti-TB drug exposure. We also examined factors that might be predictive of altered pyrazinamide absorption (CD4 + T lymphocyte count, recent food ingestion, and concurrent zidovudine administration).
METHODS

Recruitment.
The study was open to all sites in the Adult AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. HIV-infected individuals aged у13 years were eligible if they had culture-confirmed TB. Individuals with a clinical diagnosis of TB who had positive results of an acid-fast smear could be enrolled, pending culture confirmation of TB. Patients had to have been taking у2 of 4 first-line anti-TB agents (pyrazinamide, ethambutol, isoniazid, and rifampin). Patients continued taking the agents that they were taking at study entry, although, in some cases, dosing frequencies and doses were adjusted temporarily during the course of study.
Individuals were excluded if they had an aspartate aminotransferase level of 110 times the upper limit of normal (ULN), a total bilirubin level of 12.5 times the ULN, a serum creatinine level of 13 times the ULN, and/or a rate of creatinine clearance of !50 mL/min; if they were pregnant; or if they were receiving p-amino salicylic acid. Patients receiving antacids, sucralfate, didanosine, or imidazoles were eligible if administration of these agents could be separated from administration of anti-TB agents by у2 h. Patients were required to be receiving у2 of the 4 agents in a standard anti-TB regimen (isoniazid, rifampin, pyrazinamide, and ethambutol). CD4 + T lymphocyte counts were obtained within 60 days of study entry. Appropriate informed consent was obtained from all participants, and guidelines of the US Department of Health and Human Services and/or more stringent guidelines of the authors' institutions were followed.
PK sessions. Patients were scheduled to undergo 2 PK sessions: one while the patient was receiving anti-TB therapy administered as a daily regimen, and the other while the patient was receiving anti-TB therapy administered as an intermittent regimen (either twice [b.i. All patients received study-provided lots of these agents administered under direct observation on the days of PK sessions. Isoniazid (300-mg tablets) was supplied by Danbury Pharmacal, pyridoxine (50-mg tablets) and vitamin B6 were provided by Tischon Laboratories, rifampin (150-mg and 300-mg capsules) was provided by Marion Merrel Dow, and pyrazinamide (500-mg tablets) and ethambutol (400-mg tablets) were provided by Lederle Laboratories.
The time between each PK session was not fixed; however, because of the hepatic induction effects of rifamycins, patients were required to have been receiving a given regimen for у10 days before a PK session. Specimens were obtained at 2, 6, and 10 h after observed dosing. To facilitate logistics within the outpatient settings in which subjects were being treated, some flexibility was allowed around the 10-h sample time, and predose concentrations were not measured.
Laboratory methods. Whole blood samples were obtained and allowed to clot. Tubes were centrifuged; serum was transferred to cryovials containing ascorbic acid. Vials were wrapped in foil, frozen at Ϫ70ЊC within 1 h after collection, and stored at Ϫ70ЊC until shipped on dry ice for batch testing. Pyrazin- amide concentrations were measured using a reversed-phase high-performance liquid chromatography assay [21] .
Calculation of PK parameters. When results for a given subject were available for all 3 sample time points, the maximum concentration (C max ) was set to the maximum observed concentration, and the time of the C max (T max ) was set to the time of the corresponding sample. When assay results were not available for all 3 sample times, C max and T max were considered missing and were excluded from relevant analyses. The AUC was estimated using several methods.
1. AUC-L: Assuming a single compartment with loglinear elimination, a model-based AUC was calculated using all 3 time points. The area under the ascending portion of the curve (0-2 h or 0-6 h, depending on when the C max occurred) was estimated using the trapezoidal rule [22] . Actual sample times were used, and a value of zero was assumed for the predose concentration. A linear regression model was fit to the descending portion of each subject's profile, using log concentrations and actual sample times as the dependent and independent variables, respectively. The area under the descending portion of the curve was estimated as the theoretical area under the fitted log-linear curve between the actual time at which the maximum concentration was observed and 10 h. AUC-L thus represented the total 0-10-h AUC and was calculated by summing estimated areas under the ascending and descending portions of the profiles.
2. AUC-2,10h: To evaluate a 2-point PK sampling scheme, a linear trapezoidal AUC was calculated [22] using only the 2 and 10 h concentrations, provided both 2 and 10h concentrations were available.
3. AUC-D and AUC-W: Two estimates of the AUC adjusted for the dose administered were made. Dose-normalized log-linear AUCs were calculated as follows: (a) AUC-D p AUC-L/dose (in mg); and (b) AUC-W p AUC-L/dose (in mg/kg).
The elimination rate constant k e was estimated as the slope from the regression of log-concentrations on sample times, multiplied by Ϫ1 to express it as a positive number. The halflife (T 1/2 ) was estimated as log e (2) divided by the elimination rate constant.
Statistical methods. Observed concentrations at 2 h after dosing were compared to reference cut points suggested and used in the published literature [6, 8, 9, 20, [23] [24] [25] . Literaturedefined 2-h concentration cut points of 20 mg/L (low) and 10 mg/L (very low) were used for daily dosing, and 2-h concentration cut points of 25 mg/L (low) and 20 mg/L (very low) were used for intermittent dosing [6, 8, 9, 20, [23] [24] [25] . The published reference values represent the lower limits of 2-h concentrations typically achieved with standard doses of pyrazinamide among healthy adults and HIV-seronegative adults with active TB [6, 8, 9, [23] [24] [25] . The proportion of 2-h con- NOTE. AUC, area under time-concentration curve; AUC-D, AUC adjusted for dose; AUC-L, AUC estimated assuming log-linear elimination; AUC-2,10, AUC estimated using 2-and 10-h time points; AUC-W, AUC adjusted for weight; C max , maximum concentration; C2, 2-h concentration; C6, 6-h concentration; C10, 10-h concentration; CV, coefficient of variation; k e , elimination rate constant; T 1/2 , half-life; T max , time of the C max .
centrations that decreased to less than the cut points was calculated (with exact binomial 95% CIs) [26, 27] .
Differences among PK parameters were examined using the nonparametric Wilcoxon rank sum test [28] . Two-sided P values were reported. The exact (permutation-based) Wilcoxon test was used when sample sizes included !12 observations (SAS software, version 6.12; SAS Institute). If both groups contained у12 observations, a large sample approximation to the exact permutation distribution was used. This method was also used to examine the relationship between pyrazinamide PK parameters (2-h concentration and AUC-L) and the following binary variables: baseline CD4 + T lymphocyte count (!100 vs. у100 cells/mm 3 ), whether the subject ate within 2 h of receiving the dose, and whether the subject was receiving concomitant zidovudine.
The relationship between absorption rate and food ingestion within 2 h of receiving the dose was examined using Fisher's exact test. Pearson correlation coefficients were reported to summarize agreement between alternate PK parameters.
RESULTS
Fifty-nine subjects were enrolled at 8 sites in 6 states. One subject was found to be HIV-1 negative, and the results of culture were negative for TB for 1 subject. For 5 subjects, samples were lost or mislabeled. Because of medical contraindications or clinical discretion, not all subjects received anti-TB therapy including pyrazinamide. Of the 52 HIV-infected subjects with TB who received pyrazinamide, 47 underwent PK sampling while receiving daily pyrazinamide therapy, and 25 underwent PK sampling while receiving intermittent doses of pyrazinamide. Pyrazinamide PK data were available for 48 subjects (24 subjects who received daily and intermittent therapy, 23 who received daily therapy only, and 1 who received intermittent therapy only), and these data are the subject of this report. All 47 subjects who underwent sampling while receiving daily doses of therapy had specimens available at all 3 time points; 24 (96%) of 25 subjects who underwent sampling while receiving intermittent dosing had samples available at all 3 time points (1 subject lacked a 10-h sample). In 51% of PK sessions, "10-h" samples were obtained earlier than 9.5 h after dosing (range, 7:57-9:19 h); no sample was obtained later than 10:10 h after dosing. The median daily pyrazinamide dose was 2.0 g (range, 1.0-2.5 g); the median weight-adjusted daily dose was 30.8 mg/kg (range, 19.9-38.9 mg/kg). The median intermittent pyrazinamide dose was 2.5 g (range, 1.5-4.0 g); the median weight-adjusted intermittent dose was 35.4 mg/kg (range, 20.4-63.3 mg/kg).
Eighty-one percent of subjects received concomitant rifampin, 91% received isoniazid, 98% received ethambutol, and 17% received rifabutin during the daily PK session. Sixty-eight percent of subjects received concomitant rifampin, 84% received isoniazid, 76% received ethambutol, and 24% received rifabutin during the intermittent PK session. Forty percent of subjects were receiving antiretroviral therapy during the daily PK session: 23% were receiving у1 nucleoside only, 15% were receiving a regimen including an HIV protease inhibitor, and 4% were receiving a regimen including a nonnucleoside reversetranscriptase inhibitor. Thirty-two percent received antiretroviral therapy during the intermittent PK session: 8% received у1 nucleoside, 20% received a regimen including a protease inhibitor, and 16% received a regimen including a nonnucleoside reverse-transcriptase inhibitor. Subjects had eaten within 2 h of dosing of the study medication for 91% of daily dosing sessions and 72% of intermittent dosing sessions. PK parameters for pyrazinamide with daily and intermittent dosing are shown in table 2. Concentration-time curves are depicted in figure 1 . The 2-h concentration was the observed C max during daily and intermittent dosing in 94% and 83% of subjects, respectively (figure 2). Variability among the subjects for 2-h concentration determinations was modest (table 2) .
For daily pyrazinamide dosing, 2 subjects (4.3%; 95% CI, 0.8%-13.9%) had a 2-h concentration less than the low cut point of 20 mg/L, and 1 subject (2.1%; 95% CI, 0.1%-10.7%) had a 2-h concentration less than the very low cut point of 10 mg/L [6, 8, 9, 20, [23] [24] [25] . For intermittent pyrazinamide dosing, 1 subject (4.0%; 95% CI, 0.2%-18.5%) had a 2-h concentration less than the low cut point of 25 mg/L, and no subjects (0%; 95% CI, 0.0%-12.1%) had a 2-h concentration less than the very low cut point of 20 mg/L [6, 8, 9, 20, [23] [24] [25] . Of the 2 subjects with a 2-h concentration less than the literature cut point, one was receiving concomitant nelfinavir, stavudine, and lamivudine, and the other was not receiving any antiretroviral agents. The subject with a 2-h concentration that was less than the cut point during intermittent therapy was receiving zidovudine.
The mean AUC-Ls were 290.76 and 366.64 mg*h/L for daily and intermittent dosing, respectively (table 2). Coefficients of variation for AUC-L for daily and intermittent dosing were comparable and low (table 2) .
The correlation between the 2-time point AUC-2,10h and the 3-time point AUC (AUC-L) was strong (for daily dosing, the correlation coefficient was 0.93;
; figure 3 ). Sim-P ! .0001 ilarly, correlations between the single concentration obtained at 2 h and the AUC estimates-AUC-L and the 2-time point AUC-2,10h-were strong (for daily dosing, both correlation coefficients were 0.92; for both; figure 3 ). P ! .0001 Neither the 2-h concentration nor the AUC-L differed among subjects with higher (у100 cells/mm 3 ) or lower CD4 + T lymphocyte counts for either daily or intermittent dosing ( ).
The mean AUC-L for subjects receiving intermittent dosing was significantly lower among those who had eaten within 2 h of dosing (333 vs. 462 mg*h/L; ). Two-hour concen-P p .01 tration and AUC-L for daily dosing did not differ between those who did or did not eat within 2 h of dosing (42.1 ). P p .12 Mean pyrazinamide 2-h concentrations for daily dosing did not differ among subjects who were or were not taking concurrent zidovudine (40.0 vs. 42.7 mg/L;
). Mean pyra-P p .4 zinamide AUC-L values for daily dosing also did not differ among subjects who were or were not taking concurrent zidovudine (293.9 vs. 280.2 mg*h/L; ). P p .6
DISCUSSION
The mean concentration at 2 h after dosing observed for pyrazinamide in this study of HIV-infected persons with TB falls within the range of 28-55 mg/L reported in the literature for single or multiple doses in HIV-uninfected persons [8, 20, 24, 25, [29] [30] [31] . AUC estimates were also within reported ranges determined on the basis of traditional multisampling AUC determinations [23] [24] [25] 30] . Variability among the subjects for 2-h concentration and AUC determinations was modest.
The data suggest that estimates of the AUC from a 2-point sampling scheme are comparable to those obtained from a 3-point sampling scheme. Given the good correlation between the 2-h concentration alone and estimates of drug exposure from either the 2-point or 3-point sampling schemes, a single measurement at 2 h is a reasonable clinical strategy when determination of an individuals' exposure to pyrazinamide during treatment for HIV-related TB may be desirable.
The relationship between pyrazinamide drug exposure and clinical outcome in persons being treated for TB is not fully defined. In vitro, microbiologic effects are often directly proportional to drug exposure [31] [32] [33] [34] [35] . However, data specifically relating serum concentrations to clinical outcomes are very sparse for anti-TB agents in general and for pyrazinamide in particular. In a recent study of once-weekly administration of isoniazid and rifapentine, low plasma isoniazid concentrations were associated with failure of treatment and relapse [36] .
MICs of pyrazinamide for susceptible strains of M. tuberculosis, which were determined using radiometric techniques, are !6.2-50 mg/L when tested at a pH of 5.5 [34] . The recommended breakpoint for susceptibility testing is !100 mg/L. On the basis of studies of healthy volunteers and HIV-uninfected patients with TB, ranges for expected 2-h serum concentrations have been developed, yielding low and very low cut points of 20 and 10 mg/L, respectively [6, 8, 9, 20, [23] [24] [25] . When therapeutic drug monitoring is indicated or desired, these cut points may be used to evaluate 2-h pyrazinamide concentrations obtained with daily dosing.
Although pyrazinamide serum concentrations that are lower than these thresholds have been observed in HIV-infected persons [9] , the frequency with which they occur has not previously been characterized. We found that, with daily dosing, low and very low 2-h serum concentrations of pyrazinamide were uncommon: they occurred in only 4% or 2% of unselected HIV-infected subjects, respectively. The 1 subject with a very low 2-h concentration during daily therapy was receiving 30.4 mg/kg of pyrazinamide per day and concomitant nelfinavir, stavudine, and lamivudine; the subject with a low 2-h concentration was receiving 19.9 mg/kg of pyrazinamide per day and no concomitant antiretroviral agents. Similarly, with intermittent dosing, low concentrations were observed in only 1 subject (4%) who was receiving a dosage of 30 mg/kg t.i.w. and concomitant zidovudine.
The observed PK profiles of pyrazinamide in HIV-infected persons being treated for TB were reasonably uniform and predictable. Neither the degree of immunosuppression, as mea-sured by the CD4 + T lymphocyte count, nor receipt of concomitant zidovudine therapy had a significant impact on measures of drug exposure. Neither HIV infection, the presence of diarrhea, nor CD4 + T lymphocyte count contributed to interpatient variability in pyrazinamide AUC in a series from Kenya [10] .
In summary, in HIV-infected persons being treated for TB with regimens that contain pyrazinamide-even those persons with advanced immunosuppression-lower-than-expected 2-h concentrations are uncommon, and the PK of pyrazinamide are reasonably predictable. For cases in which therapeutic monitoring of pyrazinamide drug exposure is desirable because of delayed responses, concerns of potential failure, or other clinical considerations, determination of a single 2-h postdose concentration appears to be as useful as a 2-or 3-time point estimate of the AUC of pyrazinamide.
